A retrospective observational study to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK plus non-small cell lung cancer (NSCLC) treated with ALK inhibitors

被引：0
|
作者：
Biber, Josh [1 ]
Wan, Yin [1 ]
Churchill, Eric N. [2 ]
Danes, Christopher G. [2 ]
Socinski, Mark A. [3 ]
Spira, Alexander I. [4 ]
机构：
[1] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[2] Takeda Pharmaceut S Inc, Lexington, MA USA
[3] Advent Hlth Canc Inst, Orlando, FL USA
[4] Virginia Canc Specialists, Fairfax, VA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.80
引用
收藏
页码：E36 / E36
页数：1
相关论文
共 50 条
  • [31] ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK plus non-small cell lung cancer (NSCLC)
    Wolf, J.
    Oh, I-J.
    Mazieres, J.
    de Castro, J.
    Revil, C.
    Kotb, A.
    Johansdottir, H.
    Zeaiter, A.
    Novello, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] Impact of Social Economic Status on Patient Reported Outcomes (PROs) In Non-Small Cell Lung Cancer (NSCLC)
    Bachler, J.
    Wang, A.
    Poisson, L.
    Boakye, E. Adjei
    Tam, S.
    Gadgeel, S.
    Movsas, B.
    Potugari, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S716 - S716
  • [33] A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK plus NSCLC in Japan
    Tamiya, M.
    Goto, Y.
    Kenmotsu, H.
    Kurata, T.
    Murakami, S.
    Yanagitani, N.
    Taniguchi, H.
    Kuyama, S.
    Shimizu, J.
    Yokoyama, T.
    Shimada, N.
    Maeda, T.
    Tamiya, A.
    Uchiyama, A.
    Imaizumi, K.
    Takahama, T.
    Nishio, M.
    Hayashi, H.
    Shiraiwa, N.
    Okura, M.
    Kikkawa, H.
    Thomaidou, D.
    Kato, T.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S456 - S457
  • [34] Clinical Outcomes and ALK Resistance Mutations in ALK plus Non-Small Cell Lung Cancer According to EML4-ALK Variant
    Lin, J.
    Zhu, V.
    Yoda, S.
    Yeap, B.
    Jessop, N.
    Schrock, A.
    Dagogo-Jack, I.
    Gowen, K.
    Stephens, P. J.
    Ross, J.
    Ali, S.
    Miller, V.
    Gainor, J.
    Hata, A.
    Iafrate, A.
    Ou, S.
    Shaw, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1828 - S1828
  • [35] Characteristics, treatment patterns, and survival among ALK plus non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study
    Cadranel, Jacques
    Park, Keunchil
    Arrieta, Oscar
    Pless, Miklos
    Bendaly, Edmond
    Patel, Dony
    Sasane, Medha
    Nosal, Adam
    Swallow, Elyse
    Galebach, Philip
    Kageleiry, Andrew
    Stein, Karen
    Degun, Ravi
    Zhang, Jie
    LUNG CANCER, 2016, 98 : 9 - 14
  • [36] Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
    Peters, Solange
    Shaw, Alice T.
    Besse, Benjamin
    Felip, Enriqueta
    Solomon, Benjamin J.
    Soo, Ross A.
    Bearz, Alessandra
    Gadgeel, Shirish M.
    Lin, Chia-Chi
    Kao, Steven
    Seto, Takashi
    Masters, Elizabeth T.
    Abbattista, Antonello
    Clancy, Jill S.
    Thurm, Holger
    Reisman, Arlene
    Peltz, Gerson
    Camidge, D. Ross
    LUNG CANCER, 2020, 144 : 10 - 19
  • [37] Trends in ALK inhibitors for non-small cell lung cancer.
    Meade, Denise
    Ng, Marie
    Alford, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] ALK inhibitors and advanced non-small cell lung cancer (Review)
    Rossi, Antonio
    Maione, Paolo
    Sacco, Paola Claudia
    Sgambato, Assunta
    Casaluce, Francesca
    Ferrara, Marianna Luciana
    Palazzolo, Giovanni
    Ciardiello, Fortunato
    Gridelli, Cesare
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (02) : 499 - 508
  • [39] Outcomes of ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib: A Multicenter Cohort Retrospective Study.
    Xing, P.
    Wang, Q.
    Ma, D.
    Liao, X.
    Wang, M.
    Wang, Y.
    Shan, L.
    Xin, T.
    Liang, L.
    Liang, H.
    Du, Y.
    Zhang, Z.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S799 - S799
  • [40] Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) metastatic to the brain
    Chow, L. Q.
    Barlesi, F.
    Bertino, E. M.
    van den Bent, M. J.
    Wakelee, H.
    Wen, P. Y.
    Chiu, C-H.
    Orlov, S.
    Majem, M.
    Chiari, R.
    McKeage, M.
    Yu, C-J.
    Hurtado, F. K.
    Arratia, P. Cazorla
    Song, Y.
    Branle, F.
    Shi, M.
    Kim, D-W.
    ANNALS OF ONCOLOGY, 2019, 30 : 602 - 603
12345